Leonardo Biosystems & NanoMedical Systems Sign Collaboration Deal for Manufacturing Scale Up of Leonardo’s Drug Delivery Na...
28 11월 2011 - 9:00PM
Business Wire
Leonardo Biosystems, Inc. and NanoMedical Systems,
Inc. (NMS), two emerging drug delivery companies, today
announced that they have signed a development contract in which NMS
will develop and establish a commercial process to manufacture
nanoporous silicon particles for Leonardo’s multi-stage drug
delivery system.
“The expertise in the fabrication of massively-parallel
nanofluidic structures in silicon gained in the development of our
own drug delivery products enables us to support Leonardo in
bringing their manufacturing process to a commercial performance
level,” said Randy Goodall, President and CEO of NanoMedical
Systems. “Our medical device engineering quality system is designed
to produce an FDA-compliant process that will bring Leonardo to the
doorstep of clinical testing of their innovative drug delivery
products.”
With the support of university researchers and NMS, Leonardo has
formed prototype particles, demonstrating all the necessary unit
processes to make the particles. Under the collaboration, NMS will
engineer, refine, and integrate these steps in a manner that
prepares Leonardo for manufacturing particles suitable for clinical
trials.
“NMS’s familiarity with silicon materials and their capability
to do the work under an FDA-compliant quality system makes them an
ideal partner,” said Bruce D. Given, M.D., CEO of Leonardo
Biosystems. "Creation of a commercial-scale manufacturing process
compliant with regulatory requirements is on the critical path for
Leonardo to translate its exciting animal proof of concept data
into clinical reality. With NMS as a partner, we look forward to
moving ahead aggressively with our development program.”
About Leonardo’s multi-stage system
Leonardo’s lead technology consists of fully biodegradable,
porous silicon particles smaller than a red blood cell, which can
be loaded with a diverse array of secondary nanoparticles such as
liposomes, micelles, carbon nanotubes, dendrimers and metallic
nanoparticles. In addition to bypassing many of the body’s natural
defenses that lead to rapid clearance of nanoparticles administered
alone, Leonardo’s particles can be designed to seek out tumor
vasculature and can be tuned to create an intravascular depot,
providing sustained release following a single intravenous
injection.
About Leonardo Biosystems, Inc.
Leonardo Biosystems is a drug delivery company built around
technology developed by Dr. Mauro Ferrari, one of the world's
best-known nano-science innovators. Leonardo has a multi-stage
delivery platform that has been shown in animal models to be highly
effective in targeting delivery of siRNA and small molecule drugs.
Leonardo is a portfolio company of Arrowhead Research Corporation
(NASDAQ: ARWR; NASDAQ: ARWRD). For more information, please visit
www.leonardobiosystems.com.
About NanoMedical Systems, Inc.
NanoMedical Systems is a privately held, drug delivery company
developing implantable devices that use silicon nanochannel
technology invented by Dr. Mauro Ferrari, an original innovator in
the field of Bio-MEMS. NanoMedical Systems implant platform, the
Personalized Molecular Drug-delivery System includes a first
generation device (PMDS-1) customizable for months of constant
release of a wide range of drug and biologic molecules with a
second generation device (PMDS-2) that will provide variable
controlled release via programming, remote control, and sensors.
The PMDS-1 has demonstrated the sustained delivery of therapeutics
from small molecules to peptides and proteins in both in vitro and
in vivo studies. For more information, please visit
www.NanoMedSys.com.
Arrowhead Research Corp. (MM) (NASDAQ:ARWRD)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Arrowhead Research Corp. (MM) (NASDAQ:ARWRD)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024